Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS -0.33%77 Net Margin % is 43.96% as of Dec. 2025, which is 36% above its 10-year median of 32.25. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued). Among 941 Biotechnology companies, Arterra Bioscience SpA ranks better than 94.05% on this metric.
The historical rank and industry rank for Arterra Bioscience SpA's Net Margin % or its related term are showing as below:
MIL:ARBS'
s Net Margin % Range Over the Past 10 Years
Min: 23.43 Med: 32.25 Max: 42.64
Current: 42.64
MIL:ARBS's Net Margin % is ranked better than 94.05% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs MIL:ARBS: 42.64
Arterra Bioscience SpA (MIL:ARBS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Arterra Bioscience SpA Net Margin % Related Terms
Arterra Bioscience SpA Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Net Margin % distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arterra Bioscience SpA (MIL:ARBS) has a Net Margin % of 43.96% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Arterra Bioscience SpA and its competitors. This is 36% above median its historical median of 32.25. Over the past decade, Arterra Bioscience SpA's Net Margin % has ranged from 23.43 to 42.64. According to the industry distribution chart, Arterra Bioscience SpA ranks #56 out of 941 companies in the Biotechnology industry, placing it in the top 6%.
Is Arterra Bioscience SpA's Net Margin % too high?
Arterra Bioscience SpA's current Net Margin % of 43.96% is 36% above median its 10-year median of 32.25. Over the past 10 years, this metric has ranged from a low of 23.43 to a high of 42.64. Based on the distribution chart, Arterra Bioscience SpA ranks #56 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #56 out of 941 companies for Net Margin %. This places Arterra Bioscience SpA in the top 6% of its industry — outperforming the majority of peers. Historically, Arterra Bioscience SpA's own Net Margin % has ranged from 23.43 to 42.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Arterra Bioscience SpA and its competitors. Arterra Bioscience SpA's current Net Margin % is 43.96%, which is 36% above median its own 10-year median of 32.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current Net Margin % is 43.96%, which is 36% above median its 10-year median of 32.25. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Net Margin % is 43.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
Net Margin %: 43.96% (36% above median its 10-year median of 32.25)
GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score
Get the complete analysis for MIL:ARBS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
